UAB “Atsinaujinančios energetikos investicijos” publishes its NAV for September 2024
- 42
At the end of September 2024, the net asset value (NAV) of UAB “Atsinaujinančios energetikos investicijos” including success fee-accrual decreased to EUR 110,652,666 compared to the previously determined NAV at the end of June 2024 which amounted to EUR 112,755,226.
The share price including success fee-accrual decreased to EUR 1.8865 compared to the previously determined share price which at the end of June 2024, amounted to EUR 1.9223. The pro-forma internal rate of return (IRR) since inception including success fee-accrual decreased to 6.73% compared to the previously announced IRR of June 2024, which amounted to 8.12%.
At the end of September 2024, the NAV excluding success fee accrual decreased to EUR 110,652,656 compared to the previously determined NAV at the end of June 2024, which amounted to EUR 112,836,039. The share price excluding the success fee accrual decreased to EUR 1.8865 compared to the previously determined share price which at the end of June 2024, which amounted to EUR 1.9237. The IRR excluding the success fee accrual decreased to 6.73 % compared to the previously announced IRR of June 2024, which amounted to 8.15%
Contact person for further information:
Grėtė Bukauskaitė
Manager of the Investment Company
www.lordslb.lt/AEI_green_bonds
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.
- Fixing of coupon rates - Nykredit Realkredit A/S
- Notification of Share Transaction
- Rock Tech Lithium Secures $1.4 million in Federal Funding for Georgia Lake Infrastructure Development
- Infosys and Microsoft Expand Strategic Collaboration to Accelerate Customer Adoption of The Microsoft Cloud and Generative AI
- DPC Dash - Domino's Pizza China Continues to Unleash Massive Market Potential with Sustainable 4D Strategy
- Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting